Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
16
2
2020
medline:
3
3
2021
entrez:
16
2
2020
Statut:
ppublish
Résumé
Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood-brain barrier. We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lorlatinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) previously treated with ALK TKIs. In an ongoing phase II study (NCT01970865), 198 patients with ALK-positive NSCLC with ≥ 1 prior ALK TKI were enrolled into expansion cohorts (EXP) based on treatment history. Patients received lorlatinib 100 mg once daily. Patients were analyzed for progressive disease, categorized as CNS or non-CNS progression, by independent central review. Cumulative incidence probabilities were calculated adopting a competing risks approach. Fifty-nine patients received crizotinib as their only prior ALK TKI (EXP2-3A); cumulative incidence rates (CIRs) of CNS and non-CNS progression were both 22% at 12 months in patients with baseline CNS metastases (n = 37), and CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients without baseline CNS metastases [43% vs. 9% (n = 22)]. In patients who received ≥ 1 prior second-generation ALK TKI [EXP3B-5 (n = 139)], CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients both with and without baseline CNS metastases (35% vs. 23% (n = 94) and 55% vs. 12% (n = 45), respectively). Lorlatinib showed substantial intracranial activity in patients with pretreated ALK-positive NSCLC, with or without baseline CNS metastases, whose disease progressed on crizotinib or second-generation ALK TKIs. CLINICALTRIALS. NCT01970865.
Sections du résumé
BACKGROUND
Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood-brain barrier.
OBJECTIVE
We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lorlatinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) previously treated with ALK TKIs.
PATIENTS AND METHODS
In an ongoing phase II study (NCT01970865), 198 patients with ALK-positive NSCLC with ≥ 1 prior ALK TKI were enrolled into expansion cohorts (EXP) based on treatment history. Patients received lorlatinib 100 mg once daily. Patients were analyzed for progressive disease, categorized as CNS or non-CNS progression, by independent central review. Cumulative incidence probabilities were calculated adopting a competing risks approach.
RESULTS
Fifty-nine patients received crizotinib as their only prior ALK TKI (EXP2-3A); cumulative incidence rates (CIRs) of CNS and non-CNS progression were both 22% at 12 months in patients with baseline CNS metastases (n = 37), and CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients without baseline CNS metastases [43% vs. 9% (n = 22)]. In patients who received ≥ 1 prior second-generation ALK TKI [EXP3B-5 (n = 139)], CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients both with and without baseline CNS metastases (35% vs. 23% (n = 94) and 55% vs. 12% (n = 45), respectively).
CONCLUSIONS
Lorlatinib showed substantial intracranial activity in patients with pretreated ALK-positive NSCLC, with or without baseline CNS metastases, whose disease progressed on crizotinib or second-generation ALK TKIs. CLINICALTRIALS.
GOV IDENTIFIER
NCT01970865.
Identifiants
pubmed: 32060867
doi: 10.1007/s11523-020-00702-4
pii: 10.1007/s11523-020-00702-4
pmc: PMC7028836
doi:
Substances chimiques
Aminopyridines
0
Lactams
0
Lactams, Macrocyclic
0
Pyrazoles
0
lorlatinib
OSP71S83EU
Banques de données
ClinicalTrials.gov
['NCT01970865']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-65Références
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34(2):123–9. https://doi.org/10.1200/JCO.2015.62.0138 .
doi: 10.1200/JCO.2015.62.0138
pubmed: 26438117
Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer. 2013;80(3):242–8. https://doi.org/10.1016/j.lungcan.2013.02.004 .
doi: 10.1016/j.lungcan.2013.02.004
pubmed: 23453646
Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, et al. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ. 2015;18(4):312–22. https://doi.org/10.3111/13696998.2014.1003644 .
doi: 10.3111/13696998.2014.1003644
pubmed: 25565443
Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. Lung Cancer. 2016;97:43–7. https://doi.org/10.1016/j.lungcan.2016.04.006 .
doi: 10.1016/j.lungcan.2016.04.006
pubmed: 27237026
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77. https://doi.org/10.1056/NEJMoa1408440 .
doi: 10.1056/NEJMoa1408440
pubmed: 25470694
Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–8. https://doi.org/10.1200/JCO.2016.71.5904 .
doi: 10.1200/JCO.2016.71.5904
pubmed: 28475456
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38. https://doi.org/10.1056/NEJMoa1704795 .
doi: 10.1056/NEJMoa1704795
pubmed: 28586279
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–29. https://doi.org/10.1016/S0140-6736(17)30123-X .
doi: 10.1016/S0140-6736(17)30123-X
pubmed: 28126333
Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881–8. https://doi.org/10.1200/JCO.2014.59.0539 .
doi: 10.1200/JCO.2014.59.0539
pubmed: 25624436
pmcid: 4451171
Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra117. https://doi.org/10.1126/scitranslmed.3003316 .
doi: 10.1126/scitranslmed.3003316
Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016;34(24):2858–65. https://doi.org/10.1200/JCO.2015.63.5888 .
doi: 10.1200/JCO.2015.63.5888
pubmed: 27022118
Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443–5. https://doi.org/10.1200/JCO.2010.34.1313 .
doi: 10.1200/JCO.2010.34.1313
pubmed: 21422405
Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–44. https://doi.org/10.1021/jm500261q .
doi: 10.1021/jm500261q
pubmed: 24819116
Collier TL, Maresca KP, Normandin MD, Richardson P, McCarthy TJ, Liang SH, et al. Brain penetration of the ROS1/ALK inhibitor lorlatinib confirmed by PET. Mol Imaging. 2017;16:1536012117736669. https://doi.org/10.1177/1536012117736669 .
doi: 10.1177/1536012117736669
pubmed: 29067878
pmcid: 5661750
Collier TL, Normandin MD, Stephenson NA, Livni E, Liang SH, Wooten DW, et al. Synthesis and preliminary PET imaging of (11)C and (18)F isotopologues of the ROS1/ALK inhibitor lorlatinib. Nat Commun. 2017;8:15761. https://doi.org/10.1038/ncomms15761 .
doi: 10.1038/ncomms15761
pubmed: 28594000
pmcid: 5472746
Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81. https://doi.org/10.1016/j.ccell.2015.05.010 .
doi: 10.1016/j.ccell.2015.05.010
pubmed: 26144315
pmcid: 4504786
Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–9. https://doi.org/10.1016/S1470-2045(17)30680-0 .
doi: 10.1016/S1470-2045(17)30680-0
pubmed: 29074098
pmcid: 5777233
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67. https://doi.org/10.1016/S1470-2045(18)30649-1 .
doi: 10.1016/S1470-2045(18)30649-1
pubmed: 30413378
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–39. https://doi.org/10.1056/NEJMoa1810171 .
doi: 10.1056/NEJMoa1810171
pubmed: 30280657
Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AC, et al. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018;118(1):38–42. https://doi.org/10.1038/bjc.2017.395 .
doi: 10.1038/bjc.2017.395
pubmed: 29149104
Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65–72. https://doi.org/10.1200/JCO.2011.41.0639 .
doi: 10.1200/JCO.2011.41.0639
pubmed: 23213105
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9. https://doi.org/10.1001/jama.2016.9839 .
doi: 10.1001/jama.2016.9839
pubmed: 27458945
pmcid: 5313044
Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8(6):714–29. https://doi.org/10.1158/2159-8290.CD-17-1256 .
doi: 10.1158/2159-8290.CD-17-1256
pubmed: 29650534
pmcid: 5984716
Alsaggar M, Yao Q, Cai H, Liu D. Differential growth and responsiveness to cancer therapy of tumor cells in different environments. Clin Exp Metastasis. 2016;33(2):115–24. https://doi.org/10.1007/s10585-015-9761-y .
doi: 10.1007/s10585-015-9761-y
pubmed: 26476830
Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther. 2014;22(1):18–27. https://doi.org/10.1038/mt.2013.219 .
doi: 10.1038/mt.2013.219
pubmed: 24048441
Leal T, Chang JE, Mehta M, Robins HI. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7(4):319–27. https://doi.org/10.2174/157339411797642597 .
doi: 10.2174/157339411797642597
pubmed: 23251128
pmcid: 3523178
Arrondeau J, Ammari S, Besse B, Soria JC. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. J Throac Oncol. 2014;9(8):e62–3. https://doi.org/10.1097/JTO.0000000000000174 .
doi: 10.1097/JTO.0000000000000174
Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (> 15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist. 2015;20(2):224–6. https://doi.org/10.1634/theoncologist.2014-0309 .
doi: 10.1634/theoncologist.2014-0309
pubmed: 25568147
pmcid: 4319629
Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103–10. https://doi.org/10.1634/theoncologist.2018-0380 .
doi: 10.1634/theoncologist.2018-0380
pubmed: 30890623
pmcid: 6693708